SGMO ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sangamo Therapeutics, Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Sangamo Therapeutics, Inc. for potential securities fraud violations. This follows Pfizer's decision to return development and commercialization rights for a hemophilia A gene therapy candidate, impacting Sangamo's prospects.
January 12, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation for potential securities fraud following Pfizer's decision to return rights for a key gene therapy candidate, which could negatively impact its stock.
The investigation into potential securities fraud and Pfizer's decision to return rights for a key therapy candidate are significant negative developments for Sangamo. These events could lead to a loss of investor confidence and a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100